Azetidine

Azetidine

SCHEMBL2300503

C1CNC1.CC(=O)O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Azetidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103797011-A Compounds and compositions as c-Kit kinase inhibitors IRM LLC 2014-05-14 CN claimed
CN-102256977-A Purine compounds LILLY CO ELI 2011-11-23 CN claimed
CN-110520422-B Novel pyridonecarboxylic acid derivative or salt thereof 涌永制药株式会社 2023-09-05 CN disclosed
US-9340529-B2 Triazolones as fatty acid synthase inhibitors GLAXOSMITHKLINE LLC (US) 2016-05-17 US disclosed
CN-103797011-B As compound and the composition of c-Kit kinase inhibitor NOVARTIS AG (CH) 2016-03-30 CN disclosed
US-8802864-B2 Triazolones as fatty acid synthase inhibitors GLAXOSMITHKLINE LLC (US) 2014-08-12 US disclosed
CN-103797011-A Compounds and compositions as c-Kit kinase inhibitors IRM LLC 2014-05-14 CN disclosed
CN-103764653-A Compounds and compositions as c-Kit kinase inhibitors IRM LLC 2014-04-30 CN disclosed
US-20140100213-A1 TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2014-04-10 US disclosed
EP-2538787-A1 TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline LLC (US) 2013-01-02 EP disclosed
CN-102858175-A Triazolones as fatty acid synthase inhibitors GLAXOSMITHKLINE LLC 2013-01-02 CN disclosed
CN-102256977-A Purine compounds LILLY CO ELI 2011-11-23 CN disclosed
WO-2011103546-A1 TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-08-25 WO disclosed
CN-1930173-A Process for preparing cephalosporin intermediates using alpha-iodo-1-azetidineacetic acid esters and trialkylphosphites PFIZER PROD INC (US) 2007-03-14 CN disclosed
CN-1037177-C Noel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them AMERICAN CYANAMID CO (US) 1998-01-28 CN disclosed
CN-1034332-C Process for preparing 2-substituted alkyl-3-carboxy carbapenems as antibiotics AMERICAN CYANAMID CO (US) 1997-03-26 CN disclosed
CN-1034329-C Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them AMERICAN CYANAMID CO (US) 1997-03-26 CN disclosed
CN-1108648-A Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them AMERICAN CYANAMID CO (US) 1995-09-20 CN disclosed
CN-1056878-A 2-substituted alkyl-3-carboxycarbapenems as antibiotics and process for their preparation AMERICAN CYANAMID CO (US) 1991-12-11 CN disclosed
US-3962276-A ENZYME INHIBITORS ELI LILLY AND COMPANY (US) 1976-06-08 US disclosed